Clinical Scorecard: Assessing the Effectiveness of Rimegepant for Preventing Chronic and Episodic Migraine: A Three-Month Retrospective Cohort Analysis

At a Glance

Key Highlights

• Rimegepant 75 mg every other day led to significant reductions in monthly headache days and monthly migraine days.
• Improvements observed in HIT-6, MIDAS, and MSQ scores after 3 months.
• Both chronic and episodic migraine patients showed significant improvements across all outcomes.

Guideline-Based Recommendations

Diagnosis

• Chronic migraine: 15 or more headache days per month with at least 8 days meeting migraine criteria.

Management

• Rimegepant is recommended for preventive treatment of episodic migraine.

Monitoring & Follow-up

• Monitor changes in monthly headache days and migraine days, as well as patient-reported outcomes.

Risks

• Limited specific data for chronic migraine prevention; off-label use in this population.

Patient & Prescribing Data

40 adults (mean age 41.12 years; 80% women) with chronic or episodic migraine.

Rimegepant associated with meaningful reductions in migraine frequency and headache-related disability.

Clinical Best Practices

• Consider rimegepant for patients with inadequate response to traditional preventive therapies.
• Evaluate patient-reported outcomes regularly to assess treatment efficacy.

Related Resources & Content

• Clinical Trial Data
• Chinese Guidelines for the Diagnosis and Treatment of Migraine